wave
life
sciences
prices
million
public
offering
ordinary
shares
cambridge
globe
newswire
wave
life
sciences
nasdaq
wve
genetic
medicines
company
committed
delivering
treatments
people
battling
devastating
diseases
announced
today
pricing
previously
announced
underwritten
public
offering
ordinary
shares
price
public
per
ordinary
share
gross
proceeds
wave
life
sciences
offering
expected
approximately
million
deducting
underwriting
discounts
commissions
offering
expenses
ordinary
shares
offering
sold
wave
life
sciences
addition
wave
life
sciences
granted
underwriters
option
purchase
additional
ordinary
shares
terms
conditions
offering
expected
close
september
subject
customary
closing
conditions
jefferies
svb
leerink
mizuho
securities
acting
joint
managers
offering
truist
securities
wainwright
acting
offering
offering
made
means
prospectus
related
prospectus
supplement
forming
part
shelf
registration
statement
previously
filed
declared
effective
securities
exchange
commission
sec
preliminary
prospectus
supplement
accompanying
base
prospectus
relating
offering
filed
sec
september
final
prospectus
supplement
accompanying
prospectus
filed
sec
available
sec
website
located
http
copies
may
obtained
available
jefferies
llc
attention
equity
syndicate
prospectus
department
madison
avenue
floor
new
york
ny
telephone
svb
leerink
llc
attention
syndicate
department
one
federal
street
floor
boston
telephone
ext
syndicate
mizuho
securities
usa
llc
attn
equity
capital
markets
avenue
americas
floor
new
york
ny
telephone
email
press
release
shall
constitute
offer
sell
solicitation
offer
buy
sale
securities
state
jurisdiction
offer
solicitation
sale
would
unlawful
prior
registration
qualification
securities
laws
state
jurisdiction
wave
life
sciences
wave
life
sciences
nasdaq
wve
genetic
medicines
company
committed
delivering
treatments
people
battling
devastating
diseases
wave
aspires
develop
medicines
across
multiple
therapeutic
modalities
using
prism
company
proprietary
discovery
drug
development
platform
enables
precise
design
optimization
production
stereopure
oligonucleotides
driven
resolute
sense
urgency
wave
team
targeting
broad
range
genetically
defined
diseases
patients
families
may
realize
brighter
future
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
include
statements
regarding
proposed
public
offering
ordinary
shares
statements
subject
various
risks
uncertainties
actual
results
could
differ
materially
projected
wave
cautions
investors
place
undue
reliance
statements
press
release
risks
uncertainties
include
without
limitation
risks
uncertainties
related
market
conditions
satisfaction
customary
closing
conditions
related
public
offering
assurance
wave
able
complete
public
offering
anticipated
terms
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
risks
uncertainties
described
section
entitled
risk
factors
wave
preliminary
prospectus
supplement
related
proposed
offering
filed
sec
september
wave
recent
annual
report
form
filed
sec
amended
filings
wave
makes
sec
time
time
wave
undertakes
obligation
update
information
contained
press
release
reflect
subsequently
occurring
events
circumstances
investor
contact
graham
morrell
gmorrell
media
contact
alicia
suter
asuter
